ABSTRACT
The present study compared trends in antimicrobial resistance patterns in pathogens isolated from skin and soft-tissue infections (SSTIs) in Japan with those of a nationwide survey conducted in 2013. Three organisms that caused most of the SSTIs were collected from 12 dermatology departments in medical centers and 12 dermatology clinics across Japan between April 2019 and August 2020. A total of 390 strains, including 267 Staphylococcus aureus, 109 coagulase-negative staphylococci (CNS), and 14 Streptococcus pyogenes strains were submitted to a central laboratory for antimicrobial susceptibility testing. Patient demographic and clinical information was collated. Methicillin-resistant S. aureus (MRSA) was detected in 25.8% (69/267) of the S. aureus strains. The prevalence of MRSA between the present study and the 2013 survey did not differ significantly. Furthermore, there were no significant differences in MIC values and susceptibility patterns of the MRSA strains to other agents, regardless of a history of hospitalization within 1 year or invasive medical procedures. Methicillin-resistant CNS (MRCNS) was detected in 48.6% (53/109) of CNS isolates, higher than the 35.4% prevalence in the 2013 survey. This difference could be attributed to the heterogeneity in the members of the MRCNS, which comprises multiple staphylococci species, between the 2013 and 2019 surveys. However, it was noted that the susceptibility profiles of the MRCNS to each antibiotic were not significantly different from those identified in the 2013 survey. Most strains of S. pyogenes were susceptible to each antibiotic, similar to the 2013 survey. Continuous monitoring of trends in pathogen and susceptibility profiles is important to advise local public health efforts regarding the appropriate treatment of SSTIs.
Subject(s)
Dermatology , Methicillin-Resistant Staphylococcus aureus , Soft Tissue Infections , Staphylococcal Infections , Staphylococcal Skin Infections , Humans , Staphylococcus aureus , Staphylococcal Skin Infections/drug therapy , Staphylococcal Skin Infections/epidemiology , Staphylococcal Skin Infections/microbiology , Japan/epidemiology , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Staphylococcal Infections/drug therapy , Staphylococcus , Soft Tissue Infections/drug therapy , Soft Tissue Infections/epidemiology , Soft Tissue Infections/microbiology , Streptococcus pyogenes , Microbial Sensitivity TestsABSTRACT
Systemic plasmacytosis is a rare skin disorder characterized by marked infiltration of plasma cells in the dermis. IgG4-related disease is pathologically characterized by lymphoplasmacytic infiltration rich in IgG4+ plasma cells, storiform fibrosis, and obliterative phlebitis, accompanied by elevated levels of serum IgG4. Reports of cases of systemic plasmacytosis with abundant infiltration of IgG4+ plasma cells has led to discussion about the relationship between systemic plasmacytosis and IgG4-related disease. This study examined IgG4+/IgG+ plasma cell ratios in 4 patients with systemic plasmacytosis and 12 patients with other skin diseases that show marked infiltration of plasma cells. Furthermore, we examined whether these cases met one of the pathological diagnostic criteria for IgG4-related disease (i.e. IgG4+/IgG plasma cells ratio of over 40%). Only one out of 4 patients with systemic plasmacytosis met the criterion. These results suggest that systemic plasmacytosis and IgG4-related disease are distinct diseases.
Subject(s)
Autoimmune Diseases/immunology , Immunoglobulin G/analysis , Plasma Cells/immunology , Skin Diseases/immunology , Skin/immunology , Adult , Aged , Autoimmune Diseases/blood , Autoimmune Diseases/diagnosis , Biomarkers/analysis , Biomarkers/blood , Biopsy , Female , Humans , Immunoglobulin G/blood , Immunohistochemistry , Male , Middle Aged , Plasma Cells/pathology , Predictive Value of Tests , Skin/pathology , Skin Diseases/blood , Skin Diseases/diagnosisSubject(s)
Blood Component Removal , Psoriasis , Skin Diseases, Vesiculobullous , Adsorption , Granulocytes , Humans , Monocytes , Psoriasis/therapy , Treatment OutcomeABSTRACT
To investigate the trends of antimicrobial resistance in pathogens isolated from skin and soft-tissue infections (SSTI) at dermatology departments in Japan, a Japanese surveillance committee conducted the first nationwide survey in 2013. Three main organisms were collected from SSTI at 30 dermatology departments in medical centers and 10 dermatology clinics. A total of 860 strains - 579 of Staphylococcus aureus, 240 of coagulase-negative Staphylococci, and 41 of Streptococcus pyogenes - were collected and shipped to a central laboratory for antimicrobial susceptibility testing. The patient profiles were also studied. Among all 579 strains of S. aureus, 141 (24.4%) were methicillin-resistant (MRSA). Among 97 Staphylococcus epidermidis strains, 54 (55.7%) were methicillin-resistant (MRSE). MRSA and MRSE were more frequently isolated from inpatients than from outpatients. Furthermore, these methicillin-resistant strains were also isolated more frequently from patients with histories of taking antibiotics within 4 weeks and hospitalization within 1 year compared to those without. However, there were no significant differences in MIC values and susceptibility patterns of the MRSA strains between patients with a history of hospitalization within 1 year and those without. Therefore, most of the isolated MRSA cases at dermatology departments are not healthcare-acquired, but community-acquired MRSA. S. pyogenes strains were susceptible to most antibiotics except macrolides. The information in this study is not only important in terms of local public health but will also contribute to an understanding of epidemic clones of pathogens from SSTI.
Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Soft Tissue Infections/microbiology , Staphylococcal Skin Infections/microbiology , Staphylococcus aureus/drug effects , Streptococcal Infections/microbiology , Streptococcus pyogenes/drug effects , Cross-Sectional Studies , Dermatology , Hospitalization/statistics & numerical data , Humans , Japan/epidemiology , Methicillin-Resistant Staphylococcus aureus/drug effects , Microbial Sensitivity Tests , Soft Tissue Infections/epidemiology , Staphylococcal Skin Infections/epidemiology , Streptococcal Infections/epidemiologySubject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Dermatitis, Atopic/drug therapy , Adolescent , Adult , Antibodies, Monoclonal, Humanized/adverse effects , Biomarkers/blood , Dermatitis, Atopic/blood , Dermatitis, Atopic/diagnosis , Dermatitis, Atopic/immunology , Female , Humans , Japan , Leukocyte Count , Male , Middle Aged , Retrospective Studies , Severity of Illness Index , Treatment Outcome , Young AdultSubject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Chemokine CCL17/blood , Conjunctivitis/epidemiology , Dermatitis, Atopic/drug therapy , Immunoglobulin E/blood , Adult , Conjunctivitis/chemically induced , Dermatitis, Atopic/blood , Dermatitis, Atopic/diagnosis , Humans , Middle Aged , Risk Assessment , Risk Factors , Severity of Illness IndexSubject(s)
Alopecia Areata/drug therapy , Antibodies, Monoclonal, Humanized/administration & dosage , Dermatitis, Atopic/drug therapy , Quality of Life , Administration, Topical , Adrenal Cortex Hormones/administration & dosage , Adult , Alopecia Areata/complications , Alopecia Areata/diagnosis , Dermatitis, Atopic/complications , Dermatitis, Atopic/diagnosis , Follow-Up Studies , Humans , Injections, Subcutaneous , Severity of Illness Index , Treatment OutcomeSubject(s)
Bimatoprost/administration & dosage , Butanols/adverse effects , Cosmetics/adverse effects , Dermatologic Agents/administration & dosage , Hypopigmentation/drug therapy , Skin Pigmentation/drug effects , Administration, Cutaneous , Adult , Drug Administration Schedule , Female , Humans , Hypopigmentation/chemically induced , Hypopigmentation/diagnosis , Hypopigmentation/physiopathology , Treatment OutcomeSubject(s)
Pruritus/etiology , Still's Disease, Adult-Onset/complications , Aged , Biopsy , Female , Glucocorticoids/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Plasmapheresis , Prednisolone/therapeutic use , Pruritus/diagnosis , Pruritus/therapy , Severity of Illness Index , Still's Disease, Adult-Onset/diagnosis , Still's Disease, Adult-Onset/therapy , Treatment OutcomeABSTRACT
The impact of the COVID-19 pandemic on biologic treatment for psoriasis in Japan remains to be elucidated. This study aimed to investigate changes in biologic treatment and patients' behavior of visiting our department, especially in psoriasis patients treated with biologics before and during the pandemic. Data were collected from medical records retrospectively. The numbers of new psoriasis patients before (2019) and during (2020) the pandemic were compared. Patients' behavior of visiting our department was evaluated. The number of new psoriasis patients who visited our department in 2020 decreased by 35.7% compared with that in 2019. The reduction rate of new patients with psoriasis vulgaris was 49.3%, whereas the numbers of new patients with psoriatic arthritis (PsA) and generalized pustular psoriasis (GPP) were almost the same in 2019 and 2020. The number of patients who newly initiated biologics did not decrease in 2020 compared with that in 2019. As of January 1, 2020, 215 psoriasis patients were treated with biologics. Six patients (2.8%) discontinued biologics treatment possibly due to COVID-19 in 2020. Among 212 patients with good adherence to visiting our department in the previous year, 24 patients (11.3%) refrained from their visits for at least 1 month. In most cases, refrainment was observed in April and May when the first state of emergency was in effect in Japan. In conclusion, the COVID-19 pandemic hindered patients from visiting our department. However, its impact on patients who needed intensive care, such as patients with PsA and GPP, and psoriasis patients treated with biologics, was limited.
Subject(s)
Arthritis, Psoriatic , Biological Products , COVID-19 , Psoriasis , Skin Diseases, Vesiculobullous , Acute Disease , Arthritis, Psoriatic/drug therapy , Arthritis, Psoriatic/epidemiology , Biological Products/therapeutic use , COVID-19/epidemiology , Humans , Japan/epidemiology , Pandemics , Psoriasis/drug therapy , Psoriasis/epidemiology , Retrospective StudiesABSTRACT
The combination of BRAF inhibitor and MEK inhibitor is one of the first-line treatments for unresectable BRAF-mutant melanoma or as an adjuvant therapy. However, some patients who received the combination of dabrafenib and trametinib (CombiDT) or the combination of encorafenib and binimetinib (CombiEB) had adverse events (AEs) including pyrexia. We herein report a patient with BRAF-mutated melanoma who repeatedly developed elevated levels of D-dimer and pyrexia after CombiDT and CombiEB treatments. Moreover, concomitant edoxaban prevented these AEs, enabling the patient to continue receiving CombiEB.
Subject(s)
Melanoma , Skin Neoplasms , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Fever/chemically induced , Fibrin Fibrinogen Degradation Products , Humans , Melanoma/drug therapy , Melanoma/genetics , Mitogen-Activated Protein Kinase Kinases , Mutation , Protein Kinase Inhibitors/adverse effects , Proto-Oncogene Proteins B-raf/genetics , Pyridines , Pyridones/adverse effects , Skin Neoplasms/drug therapy , Skin Neoplasms/genetics , Sulfonamides/therapeutic use , ThiazolesABSTRACT
Herpes zoster (HZ) is caused by reactivation of latent varicella zoster virus (VZV) in the cranial nerve or dorsal root ganglia, with spread of the virus along the sensory nerve to the dermatome. Postherpetic neuralgia is a feared complication of HZ and impairs patients' quality of life enormously. However, there is no predictor of the duration of neuralgia. Our objective was to investigate whether there are correlations between the duration of neuralgia and serum levels of potential biomarkers in order to find practical predictors of the duration of neuralgia. Patients who were diagnosed with HZ at our hospital from April 2013 to January 2014 were included in this study. Serum levels of cytokines and other biomarkers were measured using commercial enzyme-linked immunosorbent assay kits. Thirty patients (15 men and 15 women) with HZ were enrolled in this study. The mean age was 66.1 ± 9.2 (standard deviation) years (range, 51-84 years). Four patients were evaluated as having mild, 19 as having moderate, and seven as having severe HZ. Patients with severe HZ suffered from neuralgia for a significantly longer period of time than patients with mild-to-moderate HZ (9.86 ± 8.25 months vs. 2.01 ± 2.68 months, severe vs. mild-to-moderate, p = 0.0021). The serum interleukin (IL)-10 level was significantly higher in patients with severe HZ than in those with mild-to-moderate HZ (12.93 ± 3.27 pg/mL vs. 6.74 ± 3.72 pg/mL; severe vs. mild-to-moderate; p = 0.0487). Furthermore, the serum IL-10 level was significantly correlated with the duration of neuralgia (r = 0.5193, p = 0.0111). Lastly, the serum IL-10 level significantly decreased after treatment in comparison with that before treatment (from 8.15 ± 4.46 pg/mL to 4.32 ± 11.83 pg/mL, p < 0.0001). In conclusion, these results suggest that the serum IL-10 level is an objective biomarker of the severity of HZ, and that the serum IL-10 level can be a practical predictor of the duration of neuralgia.
Subject(s)
Herpes Zoster , Neuralgia, Postherpetic , Neuralgia , Aged , Aged, 80 and over , Female , Herpes Zoster/complications , Herpes Zoster/diagnosis , Herpesvirus 3, Human , Humans , Interleukin-10 , Male , Middle Aged , Neuralgia, Postherpetic/diagnosis , Quality of LifeABSTRACT
The association of psoriasis with thyroid dysfunction has been investigated; however, it remains controversial. Some papers indicate it, and others do not. Thereby, we investigated the prevalence of thyroid dysfunction in patients with psoriasis vulgaris (PsV), psoriatic arthritis (PsA) and generalized pustular psoriasis (GPP), and the relationship between the severity of psoriasis with serum free triiodothyronine (fT3), free thyroxine (fT4) and thyroid-stimulating hormone levels. Data on 85 psoriatic patients visiting our hospital from January 2015 to November 2017 (54 men and 31 women; 51 PsV, 23 PsA 23 and 11 GPP) were retrospectively analyzed. Fourteen percent of psoriatic patients had thyroid dysfunction. The percentage of patients with thyroid dysfunction was the highest in those with GPP (45% GPP, 13% PsA, 8% PsV). Patients with thyroid dysfunction demonstrated significantly higher Psoriasis Area and Severity Index scores and elevated serum C-reactive protein (CRP) levels than those without thyroid dysfunction. A significant negative correlation was observed between the serum levels of CRP and fT3 (P = 0.0032, r = -0.4635). Our data indicate that thyroid dysfunction in patients with psoriasis is associated with inflammation caused by psoriasis.
Subject(s)
Psoriasis/complications , Thyroid Diseases/epidemiology , Thyroid Gland/immunology , Adult , Aged , C-Reactive Protein/analysis , C-Reactive Protein/immunology , Female , Humans , Male , Middle Aged , Prevalence , Psoriasis/blood , Psoriasis/diagnosis , Psoriasis/immunology , Retrospective Studies , Severity of Illness Index , Thyroid Diseases/blood , Thyroid Diseases/diagnosis , Thyroid Diseases/immunology , Thyroid Gland/metabolism , Thyrotropin/blood , Thyrotropin/metabolism , Thyroxine/blood , Thyroxine/metabolism , Triiodothyronine/blood , Triiodothyronine/metabolismABSTRACT
Psoriasis is a T-helper (Th)1/Th17-mediated, chronic inflammatory dermatitis that is commonly treated with topical corticosteroids and vitamin D3 analogs. The combination of a topical corticosteroid and vitamin D3 analog showed superior efficacy to each alone in clinical trials; however, the mechanisms by which the topical corticosteroid and vitamin D3 analog exert their effects on lesional skin in combination and each alone remain unknown. In this study, we examined the effects of combined calcipotriol (Cal)/betamethasone dipropionate (BD) ointment on psoriasis in vivo, utilizing imiquimod (IMQ)-induced murine psoriasiform skin inflammation, compared with each alone. Vehicle, Cal/BD, Cal or BD was applied on the shaved back skin for 3 consecutive days. Then, IMQ was applied for 6 consecutive days. Twenty-four hours after the last IMQ treatment, the murine skin was evaluated clinically and pathologically. mRNA expressions were examined by quantitative polymerase chain reaction. All ointments alleviated IMQ-induced psoriasiform skin inflammation clinically in comparison with vehicle application. Cal/BD suppressed mRNA expressions of cytokines involved in psoriasis pathogenesis such as interleukin (IL)-17A and IL-22 efficiently. Cal alone induced IL-10 expression, whereas BD alone reduced IL-6 mRNA expression and the number of phosphorylated signal transducer and activator of transcription 3-positive cells in lesional skin. Our study revealed that Cal and BD have different effects on IMQ-induced psoriasiform skin. Some of the immune effects of Cal and BD may be additive or synergistic, which may account for the superior clinical efficacy of their combination.
Subject(s)
Betamethasone/analogs & derivatives , Calcitriol/analogs & derivatives , Dermatologic Agents/pharmacology , Glucocorticoids/physiology , Psoriasis/drug therapy , Administration, Cutaneous , Animals , Betamethasone/pharmacology , Betamethasone/therapeutic use , Calcitriol/pharmacology , Calcitriol/therapeutic use , Cytokines/metabolism , Dermatologic Agents/therapeutic use , Disease Models, Animal , Drug Synergism , Drug Therapy, Combination/methods , Female , Gene Expression Regulation/drug effects , Gene Expression Regulation/immunology , Glucocorticoids/therapeutic use , Humans , Imiquimod/toxicity , Mice , Ointments , Psoriasis/blood , Psoriasis/immunology , Psoriasis/pathology , Skin/drug effects , Skin/immunology , Skin/pathology , Th1 Cells/drug effects , Th1 Cells/immunology , Th1 Cells/metabolism , Th17 Cells/drug effects , Th17 Cells/immunology , Th17 Cells/metabolismABSTRACT
Dupilumab shows high efficacy and tolerable safety for the treatment of atopic dermatitis (AD). However, the extent of its effectiveness varies in individual patients. To date, practical predictors of later effectiveness of dupilumab in AD patients have not been reported. To explore practical predictors of later effectiveness of dupilumab in AD, we retrospectively investigated the correlation of baseline demographics and baseline laboratory results with the percentage reduction in Eczema Area and Severity Index (EASI) scores at 1, 3, 6 and 12 months after initiating dupilumab. Furthermore, multiple regression analyses were conducted. Data were collected from patients' charts. Data on 54 Japanese adult patients (43 men and 11 women) with moderate to severe AD were analyzed. Baseline serum lactate dehydrogenase (LDH) level was negatively correlated with the percentage reduction in EASI score at 3, 6 and 12 months after initiating dupilumab but not at 1 month. Multiple regression analyses also revealed that effectiveness of dupilumab at 3 and 6 months was associated with lower baseline serum LDH level. AD patients with allergic diseases tended to have lower percentage reduction in EASI at 1 month, but had higher percentage reduction in EASI in the long term than patients without allergic diseases. In conclusion, higher baseline serum LDH level was associated with poor effectiveness of dupilumab in the long term in patients with AD. Furthermore, it tended to take a longer time for AD patients with allergic diseases to respond to dupilumab, and these patients responded better to dupilumab in the long term than patients without allergic diseases.
Subject(s)
Dermatitis, Atopic , Eczema , Adult , Antibodies, Monoclonal, Humanized , Dermatitis, Atopic/drug therapy , Female , Humans , Lactate Dehydrogenases , Male , Retrospective Studies , Severity of Illness IndexABSTRACT
Thymus and activation-regulated chemokine (TARC) is designated as a T-helper 2-type chemokine and its expression is upregulated in patients with atopic dermatitis. Previous studies reported that serum TARC levels in patients with psoriasis vulgaris (PsV) were comparable with those in healthy controls. However, the association of clinical severity of psoriasis with serum TARC levels and serum TARC levels in patients with psoriatic arthritis (PsA) or generalized pustular psoriasis (GPP) have never been reported. We investigated the association of serum TARC level with psoriasis by the type of psoriasis, and examine correlations of serum TARC levels with clinical severity scores and other results of blood tests. Data on 75 patients (51 men and 24 women; PsV, 30 patients; PsA, 29 patients; GPP, 16 patients) were analyzed. The serum TARC level was significantly higher in patients with GPP than in patients with PsV and patients with PsA. There was a positive correlation between serum TARC level and Psoriasis Area and Severity Index score (r = 0.3499, P = 0.0030). The serum TARC levels decreased after treatment in GPP patients. Our study revealed that the serum TARC level can potentially be one of the biomarkers reflecting the severity or systemic inflammation caused by psoriasis in patients with psoriasis, although not as much as in patients with atopic dermatitis. Furthermore, serum TARC levels were high in patients with GPP. Those were decreased by treatment, suggesting that serum TARC levels could be utilized as an objective biomarker to evaluate a therapeutic effect in individual GPP patients. Further accumulation of cases and further research are needed to elucidate the role of TARC in psoriasis.